Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
CONCLUSION: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes.
PRIMARY FUNDING SOURCE: European Foundation for the Study of Diabetes, supported by an unrestricted educational grant from AstraZeneca. (PROSPERO: CRD42019122043).
PMID: 32598218 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E Tags: Ann Intern Med Source Type: research
More News: AstraZeneca | Byetta | Canagliflozin | Cardiology | Cardiovascular | Dapagliflozin | Databases & Libraries | Diabetes | Diabetes Type 2 | Education | Empagliflozin | Endocrinology | Fortamet | Forxiga | Grants | Heart | Heart Failure | Insulin | Internal Medicine | Invokana | Jardiance | Metformin | Sodium | Stroke | Study | Victoza